Firicabtagene autoleucel is under clinical development by CARGO Therapeutics and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for B-Cell Non-Hodgkin Lymphoma have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Firicabtagene autoleucel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Firicabtagene autoleucel overview
Firicabtagene autoleucel (CRG-022) is under development for the treatment of pediatric, young and adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL), refractory or relapsed (r/r) Philadelphia chromosome positive acute lymphoblastic leukemia (Ph positive ALL), diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, follicular lymphoma, marginal zone B-cell lymphoma and chronic lymphocytic leukemia (CLL). It is a second generation m971 mAb-derived chimeric antigen receptors (CARs) T-cells transduced with lentivirus targeting CD22. It is administered through intravenous route as an infusion. The therapeutic candidate is developed based on the chimeric antigen receptor (CAR) technology.
CARGO Therapeutics overview
CARGO Therapeutics (CARGO) is a biotechnology company that focuses on the development of next-generation CAR T-cell therapies for cancer treatment. Its lead product is CRG-022, a novel CAR T-cell product candidate designed to target CD22, a tumor antigen expressed in most B-cell malignancies. The company also develops CRG-023 (tri-specific CAR T with CD2 co-stimulation). CARGO’s products are primarily used in the healthcare industry, specifically for the treatment of patients with large B-cell lymphoma (LBCL) and other hematologic malignancies. Its products are distributed through clinical trials and are aimed at patients who are eligible for CAR T-cell therapies but have limited access due to various challenges. The company operates primarily in the US. CARGO is headquartered in San Mateo, California, the US.
For a complete picture of Firicabtagene autoleucel’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
